Session Title: Miscellaneous
Session Date/Time: Thursday 17/09/2015 | 11:00-12:30
Paper Time: 11:16
First Author: : C.Meyer SWITZERLAND
Co Author(s): : H. Anhalm
PURPOSE:Although retinal pharmacotherapy can limit the progression of vascular AMD, many patients may suffer from loss of their reading ability due to geographic atrophy, dry AMD or scar formation. When intravitreal injections are no longer useful to increase their vision, magnifying lenses are the last option to achieve reading vision.
Department of Ophthalmology, Switzerland
Two novel macular intraocular lens (IOL) systems became available to magnify the remaining visual acuity: The Oculentis M+8 IOL is a bifocal IOL that can be implanted during cataract surgery into the capsular bag. Dr. Scharioth has designed with 1stQ Add-on IOL, that can be implanted in already pseudophacic eyes into the sulcus. Both lenses contain a magnifying part of +8 diopters. Encouraged by this latest development we selected 8 AMD patients with no reading vision and treated them unilateral by the implantation of a novel macular lens in their better eye (VA 0.2 – 0.4) while the fellow eye had a VA <0.05.
The design and implantation technique of both IOLs remain equal to the known techniques: While the Oculentis IOL may be implanted though a 2.0 mm corneal insertion similar to other bifocal IOLs; the implantation of the 1stQ Add-on IOL is performed through a 2.5 insertion, as known in toric or multifocal Add-on IOLs. No complication was noticed during the implantation, no IOL has been explanted postoperatively. Preoperative VA, size of the relative scotoma and central fixation appear useful predictors. Seven out of 8 patients achieved reading VA of 0.4-0.5 enabling them again e.g. to shop on their own.
Untreatable macular conditions with poor central vision may benefit from unilateral macular IOL implantation.